Forteo (teriparatide) does not appear to cause direct harm to teeth or oral tissues, and in fact the weight of the research points in the opposite direction: the drug seems to benefit the jawbone, gums, and the bone around tooth roots. People prescribed Forteo for osteoporosis understandably worry about oral side effects, partly because other bone-focused drugs, particularly bisphosphonates, carry well-known risks to the jaw. But teriparatide works through a fundamentally different mechanism, and its effects on the mouth are a genuinely distinct story.
How Forteo Works in the Jaw
Teriparatide is a synthetic fragment of parathyroid hormone (PTH), the hormone your body uses to regulate calcium and bone turnover. When given as a daily injection in short pulses, it triggers new bone formation rather than simply slowing bone loss. That distinction matters for oral health because the jawbone, particularly the alveolar bone that holds teeth in place, is one of the most metabolically active bones in the body. It remodels constantly in response to chewing forces, infection, and tooth movement.
Research has shown that intermittent PTH administration stimulates bone mineral content in the alveolar region specifically, supporting both periodontal repair and the success of dental implants.1PubMed. Parathyroid hormone and its effects on dental tissues In plain terms, the same mechanism that rebuilds hip and spine bone also rebuilds the bone around your teeth.
Periodontal Bone Repair
The strongest clinical evidence for Forteo’s oral effects comes from a randomized, placebo-controlled trial published in the New England Journal of Medicine. Researchers enrolled patients with severe chronic periodontitis, the kind of gum disease that eats away at the bone supporting your teeth, and gave half of them daily teriparatide injections while the other half received placebo. After one year, patients on teriparatide showed roughly 29% linear bone gain in their periodontal defects, compared with just 3% in the placebo group. Periodontal probing depth, a standard measure of how deep the pockets around teeth have become, dropped by about a third in the teriparatide group versus a fifth with placebo. Clinical attachment level, which reflects how firmly the gum holds to the tooth, also improved significantly more in the treated group.2PubMed Central. Teriparatide and Osseous Regeneration in the Oral Cavity
Those numbers are striking for anyone who has dealt with periodontal disease. Conventional treatments like scaling and root planing can clean the infection, but regrowing lost bone is notoriously difficult. A systematic review that pooled findings from eleven studies confirmed the pattern: teriparatide enhanced alveolar bone formation across multiple dental scenarios, including chronic periodontitis.3PubMed Central. Applications of Teriparatide for Alveolar Bone Regeneration: A Systematic Review No serious adverse events were reported in the trial, though the sample size was small, so rare side effects could have been missed.
Forteo and Jaw Osteonecrosis
Osteonecrosis of the jaw, where a patch of jawbone dies and becomes exposed through the gum, is one of the most feared dental complications of osteoporosis medications. It is primarily linked to bisphosphonates and denosumab, drugs that work by suppressing bone resorption. People sometimes lump all osteoporosis drugs together and worry that Forteo carries the same risk. It does not. There are no credible reports of teriparatide itself causing jaw osteonecrosis. In fact, teriparatide is being actively studied as a treatment for the condition when it is caused by other drugs.
A placebo-controlled randomized trial found that teriparatide improves the rate of resolution of medication-related osteonecrosis of the jaw (MRONJ) and represents an effective and safe treatment for it.4PubMed. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial The logic is straightforward: bisphosphonates freeze bone turnover in place, which sometimes prevents the jaw from healing normally after dental procedures. Teriparatide does the opposite, reactivating bone turnover so that dead bone can be separated and replaced. Case reports describe how activating bone turnover with teriparatide promotes separation of the dead bone fragment (sequestrum), followed by normal gum tissue growing over the exposed area.5International Journal of Implant Dentistry. Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report
A recent study comparing MRONJ patients who received teriparatide during treatment with those who did not found that the teriparatide group experienced shorter treatment periods and needed fewer surgeries. The teriparatide patients also showed significant improvements in bone density scores at the lumbar spine and femur neck, along with meaningful changes in bone metabolism markers.6PubMed Central. Treatment period and changes in bone markers according to the application of teriparatide in treating medication-related osteonecrosis of the jaw Several reviews have called teriparatide the most promising adjunctive treatment for MRONJ patients whose bone remodeling has stalled, though they stress the need for larger controlled trials before it becomes standard practice.7PubMed Central. Role of Teriparatide in Medication-Related Osteonecrosis of the Jaws (MRONJ)
Dental Implants While on Forteo
If you are taking Forteo and need a dental implant, the research is cautiously encouraging. Implant success depends on osseointegration, the process where living bone grows into the surface of the titanium screw. Anything that improves bone quality and quantity around the implant should, in theory, improve outcomes.
Animal studies have consistently supported this idea. In one study of osteoporotic rats, teriparatide treatment before implant placement significantly improved initial implant stability, the amount of bone growing into contact with the implant, and the overall volume of trabecular bone around the implant site.8PubMed Central. Pre-implantation teriparatide administration improves initial implant stability and accelerates the osseointegration process in osteoporotic rats Another animal study found that teriparatide restored peri-implant bone quality in osteoporotic rats back to essentially normal levels, with no statistical difference from healthy controls.9PubMed. Teriparatide improves microarchitectural characteristics of peri-implant bone in orchiectomized rats
Human data is thinner but points the same way. A clinical feasibility study placed small study implants in people receiving teriparatide and compared the bone that formed around them to implants in untreated controls. The teriparatide group showed more new bone volume around the implants in most compartments, providing the first human histological evidence that teriparatide can enhance implant osseointegration.10PubMed. Short-term teriparatide delivery and osseointegration: a clinical feasibility study The differences were modest, and the study was small, so no one is claiming Forteo is a guaranteed implant booster. But the direction of the evidence is reassuring if you happen to need both the drug and the surgery.
What Happens After a Tooth Extraction
Pulling a tooth leaves a socket that needs to fill in with bone. In people with osteoporosis or on bone-suppressing drugs, that healing can lag, leaving a soft or poorly mineralized socket that complicates future options like implants or dentures. Teriparatide appears to help here as well.
An animal study comparing extraction socket healing found that PTH significantly enhanced bone fill in the sockets and increased the thickness of the new trabecular bone, while also suppressing the vertical loss of alveolar bone that normally follows an extraction.11PubMed Central. Distinctive Tooth-Extraction Socket Healing: Bisphosphonate Versus Parathyroid Hormone Therapy A separate study in osteoporotic rats confirmed that teriparatide increased bone volume and decreased porosity in the healing socket, essentially normalizing the repair process that osteoporosis had impaired.12PubMed. Teriparatide improves alveolar bone modelling after tooth extraction in orchiectomized rats
These are animal studies, so the findings do not translate directly to a human sitting in a dental chair. But they are consistent enough across different models and research groups to suggest a real biological effect, and they align with what the periodontal trial in humans showed.
Orthodontic Treatment and Tooth Movement
Moving teeth with braces relies on bone remodeling: bone resorbs on the side being pushed and forms on the side being pulled. Teriparatide’s ability to accelerate both processes has attracted interest from orthodontic researchers, though mostly in animal models so far.
A systematic review of teriparatide’s influence on orthodontic tooth movement in rats found that the drug appeared to speed up tooth movement while simultaneously boosting both the bone-resorbing and bone-forming signals in the surrounding tissue.13PubMed Central. The influence of teriparatide in induced tooth movement: A systematic review More recent work has explored the mechanism, finding that PTH may reprogram inflammatory immune cells in the area into a more reparative type, which could reduce the tissue damage that sometimes accompanies aggressive tooth movement.14PubMed. Parathyroid hormone reprograms M1/M2 macrophage fate to regulate alveolar bone remodeling during orthodontic tooth movement
For anyone currently wearing braces or considering orthodontic work while on Forteo, the existing evidence is not robust enough to make clinical predictions in humans. But there is no signal that Forteo interferes with orthodontic treatment, and some reason to think it could be mildly helpful.
Root Resorption During Orthodontics
One underappreciated risk of orthodontic treatment is root resorption, where the body’s own remodeling process accidentally nibbles away at the roots of the teeth being moved. In people with osteoporosis, this risk appears to be worse. A micro-CT study in ovariectomized rats (an animal model for postmenopausal osteoporosis) found that root resorption during orthodontic movement was significantly more severe in the osteoporotic animals than in healthy controls. Teriparatide treatment significantly reduced that root resorption by day 21 of the experiment.15Journal of Oral Science Research. Effect of Teriparatide on Root Resorption during Orthodontic Tooth Movement in Ovariectomized Rats by Micro-CT
This is a single animal study, so it would be premature to tell patients that Forteo protects tooth roots during braces. But it adds to the overall picture: teriparatide’s effects on dental tissues lean consistently positive across multiple contexts.
Infections Around the Tooth Root
When a tooth’s nerve dies, bacteria can spill out the tip of the root and create a periapical lesion, an area of bone destruction at the root’s end. These lesions are what root canal treatment aims to resolve. In a mouse model, intermittent PTH administration significantly reduced the size of periapical lesions and decreased the inflammatory cell infiltration around the root apex compared to untreated controls.16PubMed Central. Intermittent administration of parathyroid hormone ameliorates periapical lesions in mice The finding suggests that the bone-building stimulus from teriparatide may help contain and heal infections at the root tip, though again this has not been confirmed in human clinical trials.
Practical Considerations for People Taking Forteo
The evidence picture here is unusual in medicine: a drug prescribed for one condition (vertebral fracture prevention) that appears to have mostly positive side effects in an unrelated area (oral health). Still, a few practical points are worth keeping in mind.
First, tell your dentist you are on Forteo. The drug’s effects on bone turnover can change what healing looks like on X-rays, and a dentist who does not know about it might misread increased bone activity as a problem rather than a normal response. Forteo is sometimes confused with bisphosphonates in busy dental offices, and that confusion could lead to unnecessary delays in treatment. Bisphosphonates call for extra caution before extractions and implant surgery; Forteo generally does not.
Second, Forteo has a two-year lifetime limit due to concerns about bone tumors observed in rodent studies at very high doses. The oral health benefits seen in trials occurred during typical treatment windows, so there is no reason to extend Forteo use solely for dental reasons. After stopping Forteo, bone density gains are typically maintained with a follow-up antiresorptive drug, but whether the specific oral bone gains persist long-term without continuation therapy is an open question the literature has not yet answered.
Third, the most robust human data for oral effects is the periodontal trial, which used standard systemic teriparatide dosing for osteoporosis. Patients did not receive any special dental formulation or local injection. That means the oral benefits appear to come along for free when you take the drug as prescribed for its approved indication.
Where the Evidence Gets Thin
Despite the encouraging direction of the research, most of the dental-specific findings come from animal models and small human studies. The periodontal trial in the New England Journal of Medicine is the standout exception, but even that study involved a limited number of patients.2PubMed Central. Teriparatide and Osseous Regeneration in the Oral Cavity Nobody has run a large, multi-center trial specifically testing whether people on Forteo have fewer tooth losses, fewer implant failures, or better outcomes after extractions than people on other osteoporosis drugs. The systematic review that pulled together eleven studies noted consistently positive effects on alveolar bone, but called for more controlled human research before clinical guidelines could be drawn.3PubMed Central. Applications of Teriparatide for Alveolar Bone Regeneration: A Systematic Review
What we can say with reasonable confidence is that Forteo does not appear to hurt your teeth or oral health. The absence of harm reports is meaningful given that the drug has been on the market since 2002 and millions of courses have been prescribed worldwide. And the available research consistently shows benefits to the jawbone, gums, and healing after dental procedures. Whether those benefits are large enough and reliable enough to factor into treatment decisions for osteoporosis, or to eventually justify prescribing teriparatide for dental indications, remains an open question that larger trials will need to settle.